On-Demand: Nuclear Pharmacy (12 hrs. CPE)

Home On-Demand: Nuclear Pharmacy (12 hrs. CPE)

On-Demand: Nuclear Pharmacy (12 hrs. CPE)

$275.00

ACCREDITATION

iCARE Pharmacy Services, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is an ACPE knowledge-based activity. Participants may receive up to 12 hours of CPE credit by attending sessions and successfully completing the CPE activity evaluation.

iCARE Pharmacy Services, Inc. is approved by the Florida Board of Pharmacy as a provider of continuing pharmacy education.

 

DISCLOSURES

Speakers have no relevant conflict of interests nor financial relationships.  All persons in a position to control the content of this activity have declared that no conflict of interest exists for this activity.

TARGET AUDIENCE
Nuclear Pharmacists and any pharmacist interested in nuclear general education.

CANCELLATION POLICY
Participants must submit cancellations in writing. Participants will receive a credit for a future CPE program.

Add to Wishlist
Category: Tag:

Description

NUCLEAR PHARMACY ON-DEMAND

Pharmacy and Therapeutics Formulary Process, A Case Study on Sincalide

Jacob Haddock, PharmD, ANP, Oklahoma University Medical Center, Clinical Pharmacist

Upon completion of this activity, pharmacists will be able to: Describe the function and oversight of the pharmacy and therapeutics (P&T) committee; Provide information required by the pharmacy director to add a generic to the formulary; Evaluate a medication for inclusion in the formulary using the example provided.

UAN: 0675-0000-23-024-H04-P

Primer on Potential Theragnostic Agents

Wendy Galbraith, PharmD, FAPhA, BCNP, Clinical Associate Professor, University of Oklahoma, Dept. of Pharmaceutical Sciences, College of Pharmacy, Nuclear Pharmacy & Research Imaging Facility

Upon completion of this activity, pharmacists will be able to: Recall radionuclides for therapy; Describe regulations for therapy radiopharmaceuticals; Identify new radiopharmaceutical therapies in the pipeline.

UAN: 0675-0000-23-025-H04-P

Nuclear Pharmacy:  Departments Questions when 795, 797, and 825 are Official – PART 1   

Jessica Comstock, PharmD, BCNP, Vice President Pharmacy Quality and Regulatory, PharmaLogic Holdings

Upon completion of this activity, pharmacists will be able to: Describe the changes taking place with the implementation of USP 825, 797, and 795; Identify the additional USP chapters that are applicable to nuclear pharmacy; Describe how internal procedures and parameters are determined and why they matter.

UAN: 0675-0000-23-026-H07-P

Sterile Preparation of I-131 Solution for Feline Hyperthyroidism

Garcia Simon, PharmD, MS, ANP, CCP, BCNP, Kindred Healthcare, Pharmacy Supervisor

Upon completion of this activity, pharmacists will be able to: Describe the treatments available for feline hyperthyroidism; Identify the methods of administration of I-131 solution; Discuss the preparation method of the sterile solution applying principles of radiation safety.

UAN: 0675-0000-23-027-H01-P

Review of the Principles Related to Scintillation Detection of Radioactive Materials

Kara Weatherman, PharmD, FAPhA, BCNP, Clinical Professor & Associate Department Head - Department of Pharmacy Practice, Director – Nuclear Pharmacy Programs, Purdue University

Upon completion of this activity, pharmacists will be able to: Review basic principles of setting up and operating a scintillation detector; Discuss the differences between single and multi-channel detectors; Describe the concept of efficiency and how this relates to accurate determination of radioactivity.

UAN: 0675-0000-23-028-H04-P

F-18 Flurpiridaz Assessment of Myocardial Perfusion-Specific Procedures

Wendy Galbraith, PharmD, FAPhA, BCNP, Clinical Associate Professor, University of Oklahoma, Dept. of Pharmaceutical Sciences, College of Pharmacy, Nuclear Pharmacy & Research Imaging Facility

Upon completion of this activity, pharmacists will be able to: Recall the properties of PET and SPECT MPI tracers; Describe the PET imaging technology used for myocardial imaging; Identify clinical applications for F-18 flurpiridaz.

UAN: 0675-0000-23-029-H01-P

Nuclear Pharmacy: Department Questions when 795, 797, and 825 are Official – PART  2

Jessica Comstock, PharmD, BCNP, Vice President Pharmacy Quality and Regulatory, PharmaLogic Holdings

Upon completion of this activity, pharmacists will be able to: Describe the changes taking place with the implementation of USP 825, 797, and 795; Identify the additional USP chapters that are applicable to nuclear pharmacy; Discuss how internal procedures and parameters are determined and why they matter.

UAN: 0675-0000-23-030-H07-P

Pharmacist’s Potential Role in Radiopharmaceutical Therapy (RPT)            

Reiko Oyama, MS, RPH, BCNP, Washington University, Director, Nuclear Pharmacy

 Upon completion of this activity, pharmacists will be able to: Describe logistical, technical, and radiation safety considerations for implementing a radiopharmaceutical therapy program; List major operating procedures for the RPT example Lu-177-PSMA; Develop your own plan for implementing a radiopharmaceutical therapy program.

UAN: 0675-0000-23-031-H04-P

 

Related products